Company intelligence / Profile preview

Qi Biodesign

Ownership: Private
Development stage: Commercial

Overview

Received biosafety certificates for gene-edited plants (high oleic acid soybean and powdery mildew disease-resistant wheat) from China's Ministry of Agriculture and Rural Affairs. Secured exemption for gene-edited high oleic acid soybean from the US Department of Agriculture.[1][2]

Therapeutic areas: Other
Modalities: Genome editing technologies
Industry: Agriculture & AgTech

Drug pipeline

2 assets

High oleic acid soybean

Commercial

Indications: Agriculture

1 more asset in the full pipeline.

Request access →

Partnerships

MGI (introduced the MGI DNBSEQ-G99 sequencer and BGI Sequencer nanopore sequencer)[2]

Beyond the preview

Go deeper on Qi Biodesign.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qi Biodesign.

Explore the full profile